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Abstract
We have developed a statistical method named IsoDOT to assess differential iso-
form expression (DIE) and differential isoform usage (DIU) using RNA-seq data. Here
isoform usage refers to relative isoform expression given the total expression of the
corresponding gene. IsoDOT performs two tasks that cannot be accomplished by ex-
isting methods: to test DIE/DIU with respect to a continuous covariate, and to test
DIE/DIU for one case versus one control. The latter task is not an uncommon situation
in practice, e.g., comparing paternal and maternal allele of one individual or comparing
tumor and normal sample of one cancer patient. Simulation studies demonstrate the
high sensitivity and specificity of IsoDOT. We apply IsoDOT to study the effects of
haloperidol treatment on mouse transcriptome and identify a group of genes whose
isoform usages respond to haloperidol treatment.
keywords: RNA-seq, isoform, penalized regression, differential isoform expression,
differential isoform usage
In the genomes of higher eukaryotes, the DNA sequence of a gene often includes mul-
tiple exons that are separated by introns. A multi-exon gene may encode several RNA
isoforms and each RNA isoform includes a subset of the exons. Recent studies have shown
that more than 90% of human genes have multiple RNA isoforms which may be differ-
entially expressed across tissues or developmental stages [Wang et al., 2008, Pan et al.,
2008], and about 75% of human genes produce multiple RNA isoforms in a given cell type
[Djebali et al., 2012]. The study of RNA-isoform expression and its regulation is of great
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importance to understand the functional complexity of a living organism, the evolutionary
changes in transcriptome [Barbosa-Morais et al., 2012], and the genomic basis of human
diseases [Wang and Cooper, 2007].
Gene expression is traditionally measured by microarrays. Most microarray platforms
provide one measurement per gene, which does not distinguish the expression of multiple
isoforms. Exon arrays can be used to study RNA isoform expression [Purdom et al., 2008,
Richard et al., 2010]. However, RNA sequencing (RNA-seq) provides much better data
for this purpose [Wang et al., 2009]. In an RNA-seq study, fragments of RNA molecules
(typically 200-500 bps long) are reverse transcribed and amplified, and then sequenced on
one end (single-end sequencing) or both ends (paired-end sequencing). A sequenced end is
called an RNA-seq read, which could be 30-150 bps or even longer. These RNA-seq reads
are mapped to reference genome and the number of RNA-seq fragments overlapping each
gene can be counted. The expression of the j-th gene in the i-th sample can be measured
by normalized fragment count after adjusting for read-depth of the i-th sample and the
length of the j-th gene [Mortazavi et al., 2008].
The major challenge for RNA isoform study is that we cannot directly observe the
expression of each RNA isoform. More specifically, an RNA-seq fragment may be com-
patible with more than one RNA isoform, and thus we cannot unambiguously assign it to
an RNA isoform. Several methods have been developed to address this challenge [Jiang
and Wong, 2009, Salzman et al., 2011, Richard et al., 2010, Xing et al., 2006, Trapnell
et al., 2010, Roberts et al., 2011, Li et al., 2010, Katz et al., 2010, Pachter, 2011, Chen,
2012]. Moreover, the annotation of RNA isoforms may not be complete or accurate and
thus one may need to reconstruct transcriptome annotation using RNA-seq data [Denoeud
et al., 2008]. Simultaneous transcriptome reconstruction and isoform abundance estima-
tion can be achieved using different approaches, including penalized regression methods
[Xia et al., 2011, Bohnert and Ra¨tsch, 2010, Li et al., 2011b,a], where each possible isoform
is treated as a covariate in a regression problem. Interested readers are referred to Ala-
mancos et al. [2014] for a comprehensive list of relevant statistical/computational methods.
Although many methods have been developed to estimate RNA isoform expression,
only a few methods have been developed to assess differential isoform expression (DIE)
while modeling biological variability and accounting for the uncertainty of isoform expres-
sion estimation. These methods include BitSeq [Glaus et al., 2012], Cuffdiff2 [Trapnell
et al., 2013], and EBseq [Leng et al., 2013]. All three methods are designed for two-group
or multi-group comparison with multiple samples per group. BitSeq (Bayesian Inference
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of Transcripts from Sequencing data) adopts a two-stage approach. The first stage is iso-
form expression estimation within each sample using a Bayesian MCMC method. The
second stage is to assess differential expression of each isoform using the posterior samples
from the first stage. Cuffdiff2 employs a likelihood-based approach for isoform expression
estimation and relevant hypothesis testing. For each gene, Cuffdiff2 first estimates expec-
tation and covariance of the expression of multiple isoforms, and then uses these estimates
to assess differential gene expression and differential isoform usage (DIU), where isoform
usage refers to the relative expression of RNA isoforms with respect to the total expression
of the corresponding gene. For differential expression, Cuffdiff2 constructs a test statis-
tic of log fold change, standardized by its standard error. Cuffdiff2 offers two tests for
differential isoform usage (DIU): for all the isoforms sharing a transcription starting site
(TSS) and for differential usage of TSSs. The test statistic for DIU is the square root
of the Jensen-Shannon divergence, divided by its standard error. While both BitSeq and
Cuffdiff2 first estimate inform expression and then perform hypothesis testing, EBSeq uses
isoform expression estimates from other methods. For two-group or multi-group compar-
ison, EBSeq assumes the (rounded) expression estimate of an isoform follows a negative
binomial distribution with group-specific mean and overdispersion. EBSeq stratifies all
the RNA isoforms into multiple categories to allow category-specific mean-variance rela-
tions. These isoform categories are constructed based on the difficulty of isoform expression
estimation. For example, genes with one, two, or more isoforms may form three categories.
BitSeq, Cuffdiff2, and EBseq all address an important issue for differential isoform
expression (DIE): to account for the uncertainty inherent in the isoform expression estima-
tion process. However, there are two types of commonly encountered tasks that cannot be
accomplished by these methods: to assess DIE with respect to a continuous variable, e.g.,
age or additive coding of genotype (i.e., 0, 1, 2, for genotype AA, AB, and BB), and to
assess DIE across two groups with only one sample per group, which is not an uncommon
situation in real data studies. For example, one may compare isoform expression between
paternal allele and maternal allele of an individual or between normal and cancer tissues
of a patient. In such situation, the RNA-seq data allow a valid statistical test, although
the population for statistical inference is limited to the tested case and control (i.e., what
happens if we collect more RNA-seq fragments) rather than the general case and control
populations (i.e., what happens if we collect more samples from case or control population).
BitSeq and EBseq cannot compare two groups with one case and one control. Cuffdiff2
provides an ad-hoc implementation for this problem. Specifically, when there is one case
and one control, Cuffdiff2 estimates isoform expression variance by combining case and
control, which implicitly assumes most isoforms are not differentially expressed. Therefore
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it is expected that Cuffdiff2 would have conservative p-value and limited power in this
situation, which is confirmed in our simulation studies.
In this paper, we develop a statistical method named IsoDOT, which assesses DIE
or DIU using RNA-seq data and addresses the aforementioned two tasks that cannot be
accomplished by existing methods. IsoDOT treats all the RNA isoforms of a gene (or a
transcript cluster of a few overlapping genes) as a unit and test whether any of these RNA
isoforms is associated with the covariate of interest. Alternative strategies would be to as-
sess differential expression or differential usage of each exon set or each RNA isoform. For
testing at exon set level, the number of tests is much larger than gene-level testing, which
increases the burden on multiple testing correction. In fact, multiple testing correction is
also more challenging because multiple exon sets of the same gene often have correlated
expression. For isoform-level testing, the major challenge is to incorporate the uncertainty
in isoform expression estimation into the testing step. It is possible that two isoforms are
very similar and thus available data cannot distinguish them. Therefore differential expres-
sion testing for these two isoforms separately is problematic. By performing testing per
transcript cluster, IsoDOT bypasses the limitation of exon-set-level or RNA-isoform-level
testing. After transcript clusters with significant DIE or DIU being identified, one may
follow up on these transcript clusters to identify differentially expressed exon sets [Anders
et al., 2012] or isoforms [Glaus et al., 2012, Trapnell et al., 2013, Leng et al., 2013].
Materials and Methods
An overview
We assume that the locations and sizes of all the exons of a gene are known. If needed,
one can use existing software (e.g., TopHat [Trapnell et al., 2009]) to detect previously un-
known exons. The inputs of our method are the bam files of all samples. From each bam
files, we will derive the number of RNA-seq fragments overlapping each exon set (an exon
set includes one or more adjacent or non-adjacent exons) and the distribution of RNA-seq
fragments’ lengths (Figure 1(a)). IsoDOT outputs the estimates of RNA isoforms’ expres-
sion across all the samples, and two p-values for each gene: one for testing differential
isoform expression (DIE) and one for testing differential isoform usage (DIU). The DIE
test asks whether the absolute expression of any isoform of a gene is associated with the
covariate of interest. In contrast, the DIU test asks, after adjusting for total expression
of the corresponding gene, whether the relative expression of any isoform of this gene is
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associated with the covariate of interest.
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Figure 1: (a) A flow chart IsoDOT work flow. The dash line indicates know isoform
annotation (i.e., transcriptome annotation) is optional. (b) A gene with 3 exons and 3
possible isoforms. (c) A matrix of input data. Each row corresponds to an exon set. The
column “Count” is the number of RNA-seq fragments at each exon set, and the columns
“isoform k” for k = 1, 2, 3 give the effective lengths of each exon set within each isoform,
and specifically, ηA,k is the effective length of exon set A for the k-th isoform. NB(µ,φ)
indicates a negative binomial distribution with mean µ, and dispersion parameter φ.
As part of IsoDOT, we have developed a penalized regression method, named IsoDetec-
tor, to estimate RNA isoform expression. In contrast to existing methods [Xia et al., 2011,
Bohnert and Ra¨tsch, 2010, Li et al., 2011b,a], IsoDetector employs penalized negative bino-
mial regression with a log penalty. The negative binomial distribution is commonly used to
model RNA-seq data, and previous studies have shown that negative binomial distribution
is able to account for the variation of RNA-seq fragment counts across biological replicates
[Langmead et al., 2010]. Many popular methods for differential expression testing, such
as DEseq [Anders and Huber, 2010] and edgeR [Robinson et al., 2010], adopt negative
binomial distribution assumption. More specifically, the negative binomial distribution
assumption, denoted by NB(µ, φ), implies that the RNA-seq fragment count across bio-
logical replicates follows a negative binomial distribution with mean value µ and variance
µ + µ2φ, where φ is an over-dispersion parameter. Therefore, the variance of a negative
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binomial distribution can be arbitrarily large for a large value of φ. The Log penalty,
which can be interpreted as iterative adaptive Lasso penalty [Tibshirani, 1996, Zou, 2006,
Sun et al., 2010], is flexible enough to handle a broad class of penalization problems [Chen
et al., 2013]. IsoDOT can test DIE/DIU against any categorical or continuous covariate
at any sample size, with or without known isoform annotation. Our simulation and real
data analysis demonstrate the satisfactory performance of IsoDOT for RNA-seq data from
human or mouse, while IsoDOT can be applied to analyze RNA-seq data of any species
that has a reference genome.
Two exons of a gene may overlap partially. In such situation, we split them into three
exons: the part that only belongs to the first or the second exon, and the part that belongs
to both exons. Multiple genes may overlap on one or more exons, and we consider these
genes as a transcript cluster. We further impose a constraint that an isoform is unlikely if
any two exons of this isoform are unlikely to belong to the same gene.
Isoform estimation in a single sample.
We study the isoforms of each transcript cluster separately, and the following discussions
apply to a specific transcript cluster. Denote the number of exons of a transcript cluster
by k. Let A be an exon set, i.e., a subset of the k exons. Let yiA be the number of sequence
fragments that overlap and only overlap with all the exons of A in the i-th sample, where
1 ≤ i ≤ n, and n is the sample size. A sequence fragment overlaps with an exon if the
“sequenced portion” of this fragment overlaps with ≥ 1 bp of the exon. For example, if
a fragment is sequenced by a paired-end read where the first end overlaps with exon 1
and 2 and the second end overlaps with exon 4, then this fragment is assigned to exon set
A = {1, 2, 4}.
To illustrate the main feature of our method, we consider a gene (which is a transcript
cluster itself) with 3 exons and 3 isoforms (Figure 1(b)). Denote its expression at sample i
by yi = (yi{1}, yi{2}, yi{3}, yi{1,2}, yi{2,3}, yi{1,3}, yi{1,2,3})T. We assume yiA follows a negative
binomial distribution ψ(µiA, φ) with unknown mean µiA and dispersion parameter φ. Let
µi be a column vector concatenating the µiA’s, then µi = E(yi). We model µi by:
µi = Xiβ =
p∑
u=1
xiuβu, βu ≥ 0, (1)
where βu is proportional to the transcript abundance of the u-th isoform, Xi = (xi1, ...,xip),
and xiu for 1 ≤ u ≤ p represents the effective lengths of all the exon sets for the u-
th isoform in the i-th sample. Intuitively, effective length is the “usable length” for
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the data generation mechanism, i.e., the number of positions where a randomly selected
sequence fragment can be sampled. The effective length of an exon set varies across the
underlying isoforms. For example, the isoform 1 and 3 of the gene shown in Figure 1(b-c)
do not include exon 2, and thus the effective length of exon set {2} is 0 for isoform 1
or 3. In contrast, the effective length of exon 2 is nonzero for isoform 2, which includes
exon 2. In addition, effective length is also a function of sample-specific RNA-seq fragment
length distribution. The typical length of RNA-seq fragments is often chosen in the RNA-
seq library preparation. However the fragment length distribution is unknown and can
be estimated from observed RNA-seq data. See Supplementary Materials Section A for
details. In this example, the design matrix includes the effective lengths of all the exon
sets for isoforms 1, 2, and 3. Next, we recast the isoform estimation problem to a negative
binomial regression problem with fragment counts yi as response and effective lengths Xi
as covariates:
yi ∼ ψ(µi, φ), and µi = Xiβ. (2)
Equation (2) should be understood such that yiA’s are independent with each other and
yiA follows a negative binomial distribution ψ(µiA, φ). The independence assumption is
reasonable because the the fragment counts across exon sets should be independent given
isoform configurations.
The regression problem presented in equation (2) is challenging because there can be a
large number of possible isoforms and their effective lengths (e.g., the columns of the design
matrix Xi) may be linearly dependent or significantly correlated. To address this difficulty,
we first select a set of candidate isoforms, and then apply a penalized negative binomial
regression to select the final set of isoforms from these candidate isoforms. The candidate
isoforms can be selected using observed RNA-seq data (Supplementary Materials Section
B) or transcriptome annotation database (e.g., Ensembl [Flicek et al., 2011]).
In our analysis, we skip the exon sets that have zero or negligible effective lengths across
all the candidate isoforms because these exon sets are not informative for isoform expression
estimation. For example, the exon set {2, 3} or {1, 2, 3} in the example shown in Figure
1 (c) are not included in the analysis. The number of candidate isoforms, denoted by p,
can be much larger than the number of (informative) exon sets, denoted by m, and there
may be high correlations among the effective lengths of the candidate isoforms. Therefore,
selecting of a final set of isoforms from the candidate isoforms is a challenging variable
selection problem. Lasso penalty has been applied in previous studies. However, the
selection consistency of Lasso requires an irrepresentability condition on the design matrix
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[Zou, 2006, Zhao and Yu, 2006], which posits that there are weak correlations between
the “important covariates”, which have non-zero effects and the “unimportant covariates”,
which have zero effects. This irrepresentability condition is often not satisfied for isoform
selection problem due to the high correlations among candidate isoforms. We employ a
Log penalty [Mazumder et al., 2011] for this challenging variable selection problem, which
does not require irrepresentability condition and can be interpreted as iterative adaptive
Lasso [Sun et al., 2010, Chen et al., 2013]. The algorithm for fitting this penalized negative
binomial regression is outlined in Supplementary Materials Section C.
Isoform estimation in multiple samples.
To estimate isoform expression in multiple samples, we have to account for read-depth
difference across samples. Let ti be a read-depth measurement for the i-th sample. For
example, ti can be the total number of RNA-seq fragments in the i-th sample, or the 75
percentile of the number of RNA-seq fragments per gene in the i-th sample [Bullard et al.,
2010]. We first consider the case without any covariate associated with isoform expression.
To account for read-depth variation, we modify equation (1) to
µi = tiXiγ =
p∑
u=1
tixiuγu, (3)
where γu is proportional to relative expression of the u-th isoform, after normalizing by ti.
Let yT = (yT1 , ...,y
T
n ), µ
T = (µT1 , ...,µ
T
n), and Z
T = (t1X
T
1 , ..., tnX
T
n), where y and µ
are vectors of length nm and Z is a matrix of size nm × p. Recall that p is the number
of candidate isoforms, n is sample size, and m is the total number of exon sets. Then the
isoform selection problem can be written as a negative binomial regression problem
y ∼ ψ(µ, φ) and µ = Zγ, where γj ≥ 0 for 1 ≤ j ≤ p. (4)
After imposing penalty, we solve this regression problem using the method described in
Supplementary Materials Section C.
Next we consider isoform estimation given a continuous covariate g = (g1, ..., gn)
T. We
assume the expression of an isoform u for sample i, denoted by γiu, is a linear function of
covariate gi: γiu = au+ b˜ugi. This linear model is an appropriate choice when gi represents
SNP genotype [Sun, 2012], which is the focus of our empirical data analysis. In this linear
model setup, a complex set of constraints is needed for au and b˜u so that γiu ≥ 0 for any
value of gi. Therefore we reformulate the problem as follows. Without loss of generality,
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we scale the value of gi to be within the range of [0,1] with the minimum and maximum
values being 0 and 1, respectively. For example, if gi corresponds to a SNP with additive
effect, we can set gi = 0, 0.5, or 1 for genotype AA, AB, or BB. Let bu = b˜u + au, then
γiu = au + (bu − au)gi = au(1− gi) + bugi. Under this model, we have
γiu ≥ 0 for any gi ∈ [0, 1] ⇔ au ≥ 0 and bu ≥ 0.
Let a = (a1, ..., ap)
T and b = (b1, ..., bp)
T, we have
µi = tiXi[a(1− gi) + bgi]. (5)
By concatenating a and b into a vector: θ = (a1, ..., ap, b1, ..., bp)
T, we can rewrite equa-
tion (5) as µi = Wiθ, where Wi = [tiXi(1 − gi), tiXigi] is an m × 2p matrix. Let
WT = (WT1 , ...,W
T
n ), then the isoform expression estimation problem reduces to a nega-
tive binomial regression problem with non-negative coefficients
y ∼ ψ(µ, φ) and µ = Wθ, where θj ≥ 0 for 1 ≤ j ≤ 2p. (6)
After imposing penalty, we solve the resulting penalized regression problem by the coordi-
nate ascend method described in Supplementary Materials Section C.
Finally we consider the general situation with q covariates, denoted by g1, ...,gq, where
gv = (g1v, ..., gnv)
T for v = 1, ..., q. Without loss of generality, we assume 0 ≤ giv ≤ 1
for 1 ≤ i ≤ n and 1 ≤ v ≤ q. Then we model γiu by γiu = qau +
∑q
v=1(bvu − au)giv =
au
∑q
v=1(1 − giv) +
∑q
v=1 buvgiv. This is simply a multiple linear regression model where
each covariate gv has its own effect. Let a = (a1, ..., ap)
T and bv = (b1v, ..., bpv)
T, then
µi = tiXi
[
a
q∑
v=1
(1− giv) + b1gi1 + · · ·+ bqgiq
]
. (7)
By concatenating a, b1, b2, ..., bq into a vector: θ = (a
T,bT1 , ...,b
T
q )
T, we rewrite the
above equation as µi = Wiθ, where Wi = [tiXi
∑q
v=1(1 − giv), tiXigi1, · · · , tiXigiq] is
an m × (q + 1)p matrix. Let WT = (WT1 , ...,WTn ), then we form an negative binomial
regression problem
y ∼ ψ(µ, φ) and µ = Wθ, for θj ≥ 0, 1 ≤ j ≤ (q + 1)p. (8)
After imposing penalty on each θj , we can solve the resulting penalized regression problem
by the coordinate ascend method described in Supplementary Materials Section C.
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When studying multiple samples, it is possible that an exon set is only expressed in
a subset of samples so that when examining the fragment counts of this exon set across
all samples, there are more 0’s than expected by a negative binomial distribution. In
such case, we introduce a zero-inflated component and employ the zero-inflated negative
binomial distribution [Rashid et al., 2011] to model RNA-seq fragment count data.
Testing for differential isoform expression.
We have described the statistical model to estimate RNA isofrom expression in multiple
samples given one or more covariate. Build on this model, we assess differential isoform
expression with respect to a set of covariates denoted by V using a likelihood ratio test.
Specifically, the null hypothesis (H0) is that buv = au for u = 1, ..., p and v ∈ V and the
alternative hypothesis (H1) is that buv 6= au for at least one pair of (u, v), where u = 1, ..., p
and v ∈ V . It is helpful to understand this test by considering two special cases. First, we
assume there is only one numerical covariate. Under H0, we solve the isoform estimation
problem by a penalized negative binomial regression with expected value µi = tiXia. Un-
der alternative, µi = tiXi[a(1− gi) + bgi]. Therefore the number of parameters is p under
H0 and 2p under H1. The asymptotic Chi-square distribution with degree of freedom p
does not apply because the models are estimated, under both H0 and H1, by penalized re-
gression. In the second special case, we assume the only variable of interest is a categorical
variable with d categories. This categorical variable can be coded as d−1 binary variables,
dented by gi1, ..., gi,d−1. The expected values of fragment counts across exon sets under H0
and H1 are µi = (d − 1)tiXia and µi = tiXi[a
∑d−1
v=1(1 − giv) + b1gi1 + · · · + bd−1gi,d−1],
respectively. Therefore the number of parameters under H0 and H1 are p and dp, respec-
tively. Again, the asymptotic Chi-square distribution with degree of freedom (d− 1)p does
not apply because the models are estimated, under both H0 and H1, by penalized regres-
sion.
We use likelihood ratio (LR) statistic as our test statistic:
LR = 2(`1 − `0), (9)
where `0 and `1 are the log likelihoods under null and alternative, respectively. Because of
penalized estimation, the null distribution of this test statistic no longer follows the stan-
dard asymptotic distribution. We obtain the null distribution by parametric bootstrap or
permutation. The parametric bootstrap approach proceeds as follows. (1) Fit the penalized
negative binomial regression under null. (2) Sampling fragment counts based on the fitted
null model. (3) Using the sampled counts to refit models under null and alternative and
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calculate the LR statistic. (4) Repeat the steps (1)-(3) a large number of times as needed
[Jiang and Salzman, 2012]. (5) Calculate the p-value as the proportion of the bootstrapped
LR statistics that are larger than LR. This parametric bootstrap procedure yields valid
p-values regardless of the sample size n. However, since the sampling population is all
the RNA-seq fragments from the studied samples, small p-values only imply significant
difference of the studied samples and should not be generalized to other individuals.
If sample size is sufficiently large (e.g., ≥ 5 cases vs. ≥ 5 controls), we can obtain
valid statistical inference for the corresponding population (instead of studied samples) by
calculating permutation p-values. Specifically, the null model is fitted without the covariate
of interest, and thus its log likelihood l0 remains unchanged across permutations. In each
permutation, we permute the covariate of interest and refit the alternative model, and then
calculate the likelihood ratio test statistic. We repeat this process a large number of times
to obtain null distribution of the likelihood ratio statistic.
Testing for differential isoform usage.
All the previous discussions, including RNA isoform expression estimation and differential
isoform expression testing, focus on absolute expression of RNA isoforms, which is RNA
isoform expression after correcting for read-depth variation across samples. Another mea-
sure of RNA isoform expression, which may be more interesting in many situations, is the
relative expression with respect to the total expression of the corresponding gene or tran-
script cluster. This is because a gene may have higher or lower expression overall, and it
may also switch the usage of some RNA isoforms. For example, a gene may predominately
use one isoform in one tissue and switch to another isoform in the other tissue. We use
the word isoform usage to refer to the relative expression of an RNA isoform. To study
isoform usage in the i-th sample, we condition on the total number of RNA-seq fragments
of the corresponding transcript cluster in the i-th sample, denoted by ri. To study RNA
isoform usage, we just need to replace ti in the aforementioned models with ri.
Results and Discussions
Simulation for case-control comparison.
We simulated ∼1 million 76 + 76 bps paired-end RNA-seq reads for a single case and con-
trol sample respectively using Flux Simulator (http://flux.sammeth.net/simulator.
html) and the Ensembl transcriptome annotations (version 67, http://useast.ensembl.
11
org/info/data/ftp/index.html) for chromosome 1 (chr1) and chromosome 18 (chr18)
for the mouse genome. We simulated the data such that all the genes from chr1 were
equivalently expressed and all the genes from chr18 were differentially expressed, either
in terms of total expression or isoform usage (Supplementary Figure 2). These simulated
RNA-seq reads were mapped to the reference genome using Tophat [Trapnell et al., 2009].
Next, we counted the number of RNA-seq fragments per exon set. It was important to
consider all exon sets rather than just exon or exon junctions because many RNA-seq frag-
ments overlap with more than two exons. For example, in this simulated dataset, ∼27% of
the paired-end reads overlapped 3 or more exons (Supplementary Figure 3). In addition,
we confirmed that the number of sequence fragments per exon set was proportional to the
effective length of the exon set (Supplementary Figure 4).
The dimension of this problem (i.e., the number of exon sets m versus the number of
candidate isoforms p) was illustrated in Supplementary Figures 5-6. Given transcriptome
annotation, p < m for the vast majority of transcript clusters, and without transcrip-
tome annotation, we restricted the number of candidate isoforms so that approximately
p < 10m. In either case, there were strong correlations among the candidate isoforms
(Supplementary Figures 7-8), therefore necessitating the use of penalized regression in
IsoDetector. After applying penalized regression, most transcription clusters included 10
or fewer isoforms, with or without transcriptome annotation (Supplementary Figures 9-10).
We compared isoform abundance estimates from IsoDetector and Cufflinks (v2.0.0)
[Trapnell et al., 2010, 2013] using the case sample. The conclusions from the control sam-
ple were similar (results not shown). We focused on 1,062 transcript clusters (corresponding
to 5,185 transcripts) that had at least 2 exons with ≥5 sequence fragments overlapping
each exon. Most of these transcript clusters included 1-2 genes and 1-42 transcripts, and
most of the 5,185 transcripts harbored 6-500 RNA-seq fragments (Figure 2a). If transcrip-
tome annotation was unavailable, the isoforms selected by IsoDetector were more similar
to the true ones than Cufflinks (Figure 2b). The two methods had similar accuracy in
terms of transcript abundance estimation, either with (Figure 2c-2d) or without (Figure
2e-2f) transcriptome annotation.
We next compared the power of IsoDOT to that of Cuffdiff (v2.0.0) [Trapnell et al.,
2013] in terms of testing for differential expression or differential isoform usage. The
results of Cuffdiff were obtained from three files: gene exp.diff (differential expres-
sion), splicing.diff (differential usage of the isoforms sharing a transcription start site
(TSS)), and promoters.diff (differential usage of TSSs). Majority of the genes in file
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Figure 2: (a) A summary of the RNA-seq data and annotation of the simulated case sample.
(d) Density curves of the distance between each de novo transcript and its closest transcript
from transcriptome annotation. The distance is defined as the ratio of the number of
unmatched base pairs over the total number of base pairs covered by either isoform. A
base pair is “matched” if it corresponds to an exon or intron location for both isoforms.
(c-d) Comparison of true transcript abundance vs. the estimates by IsoDetector or the
Cufflinks when we use known isoform annotation. Both X and Y-axes are in log10 scale.
“n” is the number of transcripts with status “OK” for either IsoDetector or Cufflinks. (e-f)
Comparison of true transcript abundance vs. the estimates by IsoDetector or Cufflinks
when we do not use any isoform annotation.
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gene exp.diff have status “OK” and they were used in the following comparison. How-
ever, no gene has status “OK” in file splicing.diff or promoters.diff. In these two
files, all the genes with meaningful p-values have status “NOTEST”, indicating that Cuffd-
iff recommends the users not to trust these testing results. The reason is as follows. For two
group comparison with one case and one control, Cuffdiff combines the case and the control
to estimate variance of biological replicates, which leads to very conservative p-value since
this approach implicitly assumes the case and the control have the same expected value.
Nonetheless, these genes with status “NOTEST” were used in the following comparison
because they are the only genes that we can use. A gene could have multiple p-values in
splicing.diff. In favor of Cuffdiff for power comparison, we used the smallest p-value
for each gene. Based on our simulation setup, power was defined as the proportion of
the genes from chr18 that had significant DIE or DIU. IsoDOT had substantially higher
power than Cuffdiff (Figure 3), attributed to the correct type I error control of IsoDOT
(Supplementary Figure 11). The poor performance of Cuffdiff is not simply a calibration
issue because IsoDOT still performs better than Cuffdiff when we compare two methods
using ROC curves (Supplementary Figure 12). Instead, poor performance of Cuffdiff is
because it tries to estimate variance across biological replicates when there is no biological
replicate at all. IsoDOT can perform a valid test because it does not try to estimate vari-
ance of biological replicates. Instead, it tries to estimate the variance due to resampling
of RNA-seq reads. To be fair, Cuffdiff does recommend such test with one case versus one
control and we include Cuffdiff in our comparison because it is the only method that allows
for such testing. In conclusion, this simulation illustrated that IsoDOT worked well in this
challenging situation of comparing one case vs. one control.
Simulation for isoform usage eQTL.
To illustrate the performance of IsoDOT in testing differential isoform usage with respect
to a continuous covariate, we applied IsoDOT to map isoform usage eQTL (gene expres-
sion quantitative trait locus) using simulated RNA-seq data and real genotype data. We
downloaded genotype data from 60 European HapMap samples [Thorisson et al., 2005]
and selected 949,537 SNPs with minor allele frequency (MAF) > 0.05 for the following
analysis. We defined transcription clusters based on Ensembl annotation (version 66,
http://useast.ensembl.org/info/data/ftp/index.html), and selected 200 transcript
clusters that satisfied the following two conditions for our simulation studies. (1) Each
transcript cluster has > 1 annotated RNA-isoforms, and (2) Each transcript cluster has
≥ 1 SNP on the gene body (any intronic or exonic regions) or within 1000bp of the gene
body. For each selected transcript cluster, we simulated RNA-seq fragment counts across
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exon sets under null (H0) and alternative (H1), respectively. Specifically, for each gene, we
randomly selected 50% the isoforms to have zero expression and set the expression of the
other 50% of isoforms by drawing γu (equation (4)) from a uniform distribution U[0.5, 1].
Then using these simulated data, we assessed the differential isoform usage of each
transcript cluster with respect to each of the nearby SNPs (within 1000bp of the gene
body) and kept the most significant eQTL per transcript cluster. For each transcript
cluster, up to 1000 permutations were carried out to correct for multiple testing across the
multiple nearby SNPs. Under H0, the permutation p-values followed uniform distribution;
and under H1, the permutation p-values were obviously enriched with small values (Figure
4(a)). In this simulation, we had ∼ 80%/40% power to detect local isoform usage eQTL
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Figure 4: Simulation results for testing isoform-usage eQTL on 200 transcription clusters.
(a) The qq-plot for p-values distributions against expected uniform distribution. (b) Power
(H1) or type I error (H0) for different p-value cutoffs.
for permutation p-value cutoffs 0.05 and 0.005, respectively (Figure 4(b)). Therefore this
simulation demonstrate that IsoDOT correctly control type I error and has power to detect
differential isoform usage with respect to a continuous covariate.
Haloperdiol treatment effect on mouse transcriptome.
Haloperidol is a drug to treat schizophrenia, acute psychotic states, and delirium. An ad-
verse side effect of chronic haloperidol treatment is tardive dyskinesia (TD). Haloperidol-
induced vacuous chewing movements (VCMs) in mice is a valid animal model for TD
[Crowley et al., 2012]. We applied IsoDOT to analyze RNA-seq data for mice treated
with haloperidol vs. placebo with particular interest in identifying genes responding to
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haloperidol treatment and/or responsible for VCM. RNA-seq data were collected from
whole brains from four mice: two C57BL/6J mice treated with haloperidol or placebo and
two 129S1Sv/ImJ×PWK/PhJ F1 mice treated with haloperidol or placebo. Each RNA-seq
fragment was sequenced on both ends by 93 or 100bp, and 20-27 million RNA-seq reads
were collected for each mouse (Supplementary Table 1). See Supplementary Materials Sec-
tion D for additional details of the experiment.
We first studied differential isoform expression/usage between two C57BL/6J mice.
RNA-seq reads were mapped to the mm9 reference genome using TopHat [Trapnell et al.,
2009]. At FDR of 5%, IsoDOT identified 86 or 88 genes with differential isoform usage
(DIU), with or without transcriptome annotation, respectively. For the test of differential
isoform expression (DIE), also at FDR of 5%, IsoDOT identified 332 or 206 genes with or
without transcriptome annotation, respectively. We sought to gain some insight of these
four gene lists by applying functional category enrichment analysis [Sherman et al., 2009]
on the top 100 genes in each list. Only those DIU genes identified with transcriptome
annotation were significantly associated with biologically relevant categories such as neu-
ron projection (Supplementary Figure 13-16). This implied that DIU, rather than DIE,
might be more relevant to haloperidol treatment in C57BL/6J mice. The gene lists identi-
fied without transcriptional annotation did not show functional enrichment, which implied
larger sample size or higher read-depth were needed to detect DIE or DIU without tran-
scriptome annotation. According to Cuffdiff manual, it is not recommended to run Cuffdiff
with sample size one versus one. However, we still evaluated the performance of Cuffidff
in this dataset for comparison purpose. Using the results reported by Cuffdiff, no gene
has q-value smaller than 0.05 (with or without annotation, alternative promoter or alter-
native splicing), and functional category enrichment analysis [Sherman et al., 2009] on the
top 100 genes reported by Cuffdiff identified no significantly enriched functional category
(Supplementary Figure 17).
In the following, we discuss in more details several DIU genes identified by IsoDOT,
which can be potential targets for follow up studies (Supplementary Table 2). For example,
Utrn (utrophin, Figure 5) and Dmd (dystrophin) are both involved in neuron projection
and could be candidates underlying the VCM side effect. Grin2b (glutamate receptor,
ionotropic, NMDA2B, Supplementary Figure 18) or its human ortholog is involved in
Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), which
are potentially relevant to the VCM side effect of haloperidol treatment. In addition,
our previous studies had prioritized several other glutamate receptors such as Grin1 and
Grin2a as candidates that response to haloperidol treatment using independent data and
17
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methods [Crowley et al., 2012].
Similar studies were conducted for the two F1 mice of 129S1Sv/ImJ×PWK/PhJ.
To better map RNA-seq reads, we first built two pseudogenomes for 129S1Sv/ImJ and
PWK/PhJ by incorporating Sanger SNPs and indels [Keane et al., 2011] into reference
genome and mapped the RNA-seq reads to the two pseudogenomes separately. Then align-
ments were remapped back to the reference coordinate system and the observed genetic
variants were annotated for each RNA-seq fragment. IsoDOT identified much less DIU or
DIE genes in these two F1 mice than in the two C57BL/6J mice. At FDR 0.2, no DIU
genes were identified and 85 DIE gene were identified. Six of these 85 genes were involved
in actin-binding, though this functional category was not significantly overrepresented.
The greater level of DIE and DIU in C57BL/6J than 129S1Sv/ImJ×PWK/PhJ follow-
ing chronic haloperidol treatment was consistent with behavioral phenotype data which
showed that C57BL6/J mice had greater susceptibility to haloperidol-induced VCM (Sup-
plementary Figure 19) [Crowley et al., 2012]. Therefore, some of the C57BL/6J transcrip-
tional changes detailed in this study might contribute to the development of haloperidol-
induced VCM.
Allele-specific differential isoform usage.
About 37.2% of the RNA-seq fragments from the two 129S1Sv/ImJ×PWK/PhJ F1 mice
were only mapped to paternal or maternal allele or were mapped to one allele with less
mismatch, and hence they were allele-specific RNA-seq fragments. There was no genome-
wide bias, i.e., ∼50% of the allele-specific RNA-seq fragments were mapped to each parental
strain (Supplementary Table 1). Using these allele-specific RNA-seq fragments, we applied
IsoDOT to assess differential isoform usage between maternal and paternal alleles. At a
liberal FDR cutoff 0.2, no DIU gene was identified, and 19 or 30 DIE genes were identified
from the haloperidol/placebo treated F1 mice, respectively. The genes with significant
differential isoform usage in the haloperidol treated mice, but not the placebo treated
mice might indicate genetic×treatment interactions. Supplementary Table 3 listed 23 such
genes with DIU p-values < 0.01 in the haloperidol treated mice, and DIU p-values >
0.1 in the placebo treated mice. Among them, Synpo and Snap25 are associated with
neuron functions. Snap25 is known to be associated with schizophrenia and/or haloperidol
treatment at DNA [Mu¨ller et al., 2005], RNA [Sommer et al., 2010], and protein levels
[Thompson et al., 1998, Honer et al., 2002]. To the best of our knowledge, this is the first
report that the differential isoform usage of Snap25 is associated with genetic×haloperidol
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treatment interaction.
Software and data availability.
An R package of IsoDOT is available at http://www.bios.unc.edu/~weisun/software/
isoform.htm. Testing differential isoform expression/usage is computationally intensive.
Using IsoDOT with up to 1,000 parametric bootstrap, it will take on average 1-3 minutes
to test differential isoform usage for a gene on a single processor. Parallel computation is
needed and straightforward for genome-wide study. We are also actively working on imple-
menting our method using Graphics Processing Unit (GPU) using the massively parallel
algorithm described in Supplementary Materials Section E. Simulated RNA-seq data can be
downloaded from http://www.bios.unc.edu/~weisun/software/isoform_files/. The
RNA-seq data of mouse haloperidol treatment experiment are available from NCBI GEO
(GSExxx).
Discussion
We have developed a new statistical method named IsoDOT to assess differential isoform
expression or usage from RNA-seq data with respect to categorical or continuous covari-
ates. The resampling based approach is the basis of our hypothesis testing method. Two
components of our method, the negative binomial distribution assumption and the Log
penalty for penalized estimation are important for the success of this resampling based
approach. First, negative binomial distribution is a well-accepted choice to model RNA-
seq fragment data across biological replicates. For the self-completeness of our paper, we
also demonstrate that negative binomial distribution can provide good fit of RNA-seq frag-
ment count data, while Poisson distribution assumption leads to severe underestimate of
variance (Supplementary Figure 20). Replacing the Log penalty with the Lasso penalty
in IsoDOT leads to inaccurate type I error control and/or reduced power (Supplementary
Figure 21). The limitation of Lasso is especially apparent when we do not use isoform
annotation, where the number of candidate isoforms is much larger than sample size. This
is consistent with the previous findings that the Lasso tends to select more false positives
and has larger bias in effect estimates than the Log penalty [Chen et al., 2013].
Some biases should be accounted to obtain better estimates of RNA isoform abundance.
For example, the RNA-seq reads may not be uniformly distributed along the transcript,
and DNA sequence features such as GC content may affect the abundance RNA-seq reads.
Such biases, if exits, affect both the likelihoods under null and alternative and do not alter
our Type I error rate; furthermore, it may have limited impact to the power of testing
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because we calculate p-values by resampling approaches. For example, if the last exon of
a gene tends to have larger number of RNA-seq reads, our method may overestimate the
expression of the isoform harboring the last exon. However, such over-estimation occurs
under both null and alternative and does not lead to inflated or deflated type I error.
Systematically accounting for such bias is among our future works to further improve the
performance of IsoDOT.
An important contribution of IsoDOT is to allow assessing differential isoform usage
between one case and one control sample. This is especially important for paired samples,
e.g., maternal and paternal alleles of one individual. When there are multiple paired sam-
ples, we can combine the p-values of multiple pairs using meta-analysis via Fisher’s method
or Stouffer’s Z-score [Hunter et al., 1982]. In the preliminary study reported in this paper,
we have identified several interesting genes (Utrn, Dmd, Grin2b, Snap25 ) whose isoform
usage may respond to haloperidol treatment or its side effect. In the near future, we plan
to extend this study to include larger number of mice with diverse genetic backgrounds
including mice from the Collaborative Cross [Churchill et al., 2004, Consortium, 2012].
Recently developed sequencing techniques can deliver longer reads such as 2 x 250 bp
reads from Illumina’s MiSeq or 400 bp reads from Ion Torrent. Our methods can handle
these longer sequencing reads without any difficulty. When the RNA-seq reads are long
enough, transcriptome reconstruction becomes easier. However, until all the isoforms of a
transcript cluster can be unambiguously reconstructed and all the RNA-seq fragments can
be assigned to an isoform with (almost) 100% certainty, testing differential isoform expres-
sion/usage remains a challenging problem where methods and software such as IsoDOT
are needed. Another recent development of RNA-seq technique is to deliver “stranded”
sequences so that RNA-seq from sense and antisense strands can be separated. For the
analysis of such stranded RNA-seq data, the only step of IsoDOT pipeline that needs to
be modified is to count the RNA-seq fragments for sense and anti-sense strands separately.
This work was partially supported by NIH grants GM105785, CA167684, CA149569,
MH101819, GM074175 and P50 HG006582.
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Supplementary Materials
A Calculation of effective length
An RNA-seq fragment is a segment of RNA to be sequenced. Usually only part of an
RNA-seq fragment is sequenced: one end or both ends, hence single-end sequencing or
paired-end sequencing. All the discussions in this section are for paired-end reads, though
the extension to single-end reads is straightforward. The minimum fragment size is the
read length, denoted by d. This happens when the two reads of a fragment completely
overlap. We impose an upper bound for the fragment length based on prior knowledge of
the experimental procedure and denote the upper bound by lM . Then the fragment length
l satisfies d ≤ l ≤ lM . We denote the distribution of the fragment length for sample i by
ϕi(l), which can be calculated using observed read alignment information.
For the i-th sample, the effective length of exon j of rj base pairs (bps) is
ηi,{j} = f(rj , d, lM , ϕi) =

0 if rj < d
min(rj ,lM )∑
l=d
ϕi(l)(rj + 1− l) if rj ≥ d
.
If rj < d, the exon is shorter than the shortest fragment length, and thus the effective
length of this exon is 0. In other words, no RNA-seq fragment is expected to overlap and
only overlap with this exon. If rj ≥ d, the effective length is rj + 1 − l, i.e., there are
rj + 1 − l distinct RNA-seq fragments that can be sequenced from this exon (Figure S1).
Then
∑min(rj ,lM )
l=d ϕi(l)(rj + 1− l) is summation across all likely fragment lengths, weighted
by the probability of having fragment length l.
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the i-th sample across all genes. The reason is as follows. The original link function
c n be written as µ i = TiXg = Ri(Ti/Ri)Xg , where (Ti/Ri) measures the total ex-
pression of the gene in the ith sample. Then skipping the ratio (Ti/Ri) in the original
link function leads to the new link function, which is equivalent to assuming this
gene has a constant expression rate across samples.
3.3 Calculation of effective length
An RNA-seq fragment is a segment of RNA to be sequenced. Usually only part of an
RNA-seq fragment is sequenced: on end or both ends, hence singl -end sequenc-
ing or paired-end sequencing. All the discussions in this section are for paired-end
reads, though the extension to single-end reads is straightforward. The minimum
fragment size is the read length, denoted by d. This happens when the two reads of
a fragment completely overlap. We impose an upper bound for the fragment length
based on prior knowledge of the experimental procedure and denote th upp r bound
by lM . Then the fragment length l satisfies d  l  lM . We denote the distribution of
the fragment length for sample i by ji(l), which can be calculated using observed
read alignment information. The fragment length distribution is incorporated in our
model to allow across-sample variations due to the differences in fragment length
distribution.
We define the effective length of exon j of r j base pairs (bps), in the i-th sample
by
hi,{ j} = f (r j,d, lM,ji) =
8><>:
0 if r j < d
min(r j ,lM)
Â
l=d
ji(l)(r j+1  l) if r j   d
.
In the following discussions, to simplify the notation, we skip the subscript of i. For
two exons j and k ( j < k) of lengths r j and rk, which are adjacent in the transcript,
the effective length for the fragments that cover both exons is
h{ j,k} = f (r j+ rk,d, lM,j) h{ j} h{k}. (3)
For three exons j, h, and k ( j < h< k) of lengths r j, rh and rk, which are adjacent in
the transcript, the effective length for the fragments that cover all three exons is
h{ j,h,k} = f (r j+ rh+ rk,d, lM) h{ j,h} h{h,k} h{ j,(h),k} h{ j} h{h} h{k},
where h{ j,(h),k} is the effective length in the scenario that the transcript covers con-
secutive exons j, h, and k, whereas the observed paired-end read only covers exons
j and k.
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the effective length for the fragments that cover both exons is
h{ j,k} = f (r j+ rk,d, lM,j) h{ j} h{k}. (3)
For three exons j, h, and k ( j < h< k) of lengths r j, rh and rk, which are adjacent in
the transcript, the effective length for the fragments that cover all three exons is
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Figure S1: An illustration of effective length calculation for an exon of rj bps and RNA-
seq fragment of l bps. The orange box indicates the exon and the black lines above the
orange box indicate two RNA-seq fragments, while each RNA-seq fragment is sequenced
by a paired-end read. There are rj + 1− l distinct choices to select an RNA-seq fragment
of l bps from this exon, and thus the effective length is rj + 1− l.
27
In the following discussions, to simplify the notation, we skip the subscript of i. For
two exons j and k (j < k) of lengths rj and rk, which are adjacent in the transcript, the
effective length for the fragments that cover both exons is
η{j,k} = f(rj + rk, d, lM , ϕ)− η{j} − η{k}. (10)
For three exons j, h, and k (j < h < k) of lengths rj , rh and rk, which are adjacent in the
transcript, the effective length for the fragments that cover all three exons is
η{j,h,k} = f(rj + rh + rk, d, lM )− η{j,h} − η{h,k} − η{j,(h),k} − η{j} − η{h} − η{k},
where η{j,(h),k} is the effective length in the scenario that the transcript covers consecutive
exons j, h, and k, whereas the observed paired-end read only covers exons j and k.
η{j,(h),k} =

0 if (rj , rh, rk) ∈ R1
min(rj+rh+rk,lM )∑
l=2d+rh
ϕ(l)δl otherwise
where R1 = {(rj , rh, rk) : rj < d or rk < d or rh + 2d > lM}, and δl = min(rj , l − rh −
d) − max(d, l − rh − rk) + 1. The above formula is derived by the following arguments.
Let lj and lk be the lengths of the parts of the fragment that overlaps with exon j and
k, respectively. Given l, the restriction of lj and lk are l = lj + lk + rh, d ≤ lj ≤ rj , and
d ≤ lk ≤ rk, and thus the range of lj is max(d, l − rh − rk) ≤ lj ≤ min(rj , l − rh − d). For
more than 3 consecutive exons, the effective lengths can be calculated using recursive calls
to the above equations.
In practice, a few sequence fragments may be observed even when the effective length is
zero, which may be due to sequencing errors. To improve the robustness of our method, we
modify the design matrix X by adding a pre-determined constant eLenMin to each element
of X.
B Selection of candidate isoforms
For each gene, we select a set of candidate isoforms given the fragment counts at each exon
set. We define a start exon as an exon that is only connected to downstream exons and an
end exon as an exon that is only connected to upstream exons. An initial set of start and
end exons can be identified simply by examining the observed exon sets.
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Next, we seek to find more start and end exons by identifying break points where the
read-depth of two adjacent exons are different. Specifically, suppose the gene of interest has
h exons. Let y{k} be the number of fragments overlapping the kth exon of this gene. We
apply a Pearson chi-squared test to assess whether the frequency distribution of y{k−1} and
y{k} is significantly different from theoretical expectation based on their effective lengths.
For k = 2, ..., h, there are h − 1 possible break points, which correspond to h − 1 p-
values: pB1, ..., pBh. We order those possible break points by the corresponding p-values
in ascending order and select the top
min
(
maxBreaks,
h∑
k=2
I(pBk < pvalBreaks)
)
break points, where I(·) is an indicator function, maxBreaks and pvalBreaks are two pre-
set parameters. maxBreaks is the maximum number of break points, with default value
5, and pvalBreaks is a p-value cutoff, with default value 0.05. If the k-th break points is
selected, the (k− 1)th exon is added to the set of start exons and the kth exon is added to
the set of end exons. After identifying all possible start and end exons, we can construct
all isoforms that have consecutive exons.
For each exon set, we assign a p-value to quantify whether it is expressed. Suppose there
are nT fragments for the gene of interest and among them nj fragments are from the jth
exon set. Then the expression p-value is pEj = pbinom(nj , nT , lj/lT ), where pbinom(·, n, pi)
is cumulative binomial distribution function with n trials and probability of success pi, lj
is the effective length of the jth exon set, and lT is the total effective length of this gene.
We claim the jth exon set is expressed if
pEj ≥ pvalExpress and
nj/lj
nT /lT
> foldExpress,
where pvalExpress and foldExpress are two pre-set parameters, with default values 0.01
and 1/5, respectively.
Finally, we select all the expressed exon sets that harbor at least on exon-skipping
event, and order them by the pEj in a descending order. Then for each of these ordered
exon sets, we construct new RNA-isoforms by inserting this exon set into each existing
isoform if this exon set is compatible with the isoform. We stop adding more isoforms if
either
q/m > pMaxRel or q > pMaxAbs
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where q is the number of isoforms, pMaxRel and pMaxAbs are pre-set parameters with de-
fault values 10 and 2000, respectively. In oder words, we allow the number of isoforms to
be at most 10 times the number of exon sets and the total number of isoforms to be at
most 2000. Users can change these default values. Our penalized regression can handle
the situation pMaxRel=100 and pMaxAbs=100,000; however it may significantly reduce the
computational efficiency.
C Model fitting of the penalized negative binomial regres-
sion
Let f(yi;µi, φ) be the density function for a negative binomial distribution with mean µi
and dispersion parameter φ (hence variance µi + φµ
2
i ):
f(yi;µi, φ) =
Γ(yi + 1/φ)
yi!Γ(1/φ)
(
1
1 + φµi
)1/φ( φµi
1 + φµi
)yi
. (11)
As φ → 0, f(yi;µi, φ) converges to Poisson distribution with mean µi. While all the
following discussions focus on negative binomial distribution, they can be easily extended
to Poisson situation and we omit the details here. Using negative binomial distribution,
the log likelihood is
l(y,µ, φ) =
n∑
i=1
[
log
(
Γ(yi + 1/φ)
yi!Γ(1/φ)
)
+ yi log
(
φµi
1 + φµi
)
− 1
φ
log(1 + φµi)
]
, (12)
where y = (x1, ..., xn)
T, µ = (µ1, ..., µn)
T, and n indicates sample size. We further assume
µi =
∑J
j=1 xijbj , where bj ≥ 0, and maximize the penalized log likelihood
l(y,µ, φ)−
p∑
j=1
q(bj), (13)
where q(bj) = λ log(bj + τ), and λ and τ are two tuning parameters. In contrast to
conventional penalized GLM, we employ a non-canonical link function, does not use an
intercept, and impose a set of constraints that bj ≥ 0 for j = 1, 2, ..., J . We maximize
the likelihood by iteratively updating regression coefficients bj and dispersion parameter
φ. Following Friedman et al. ?, we approximate the likelihood part in equation (13) by a
quadratic approximation:
lQ(y,µ, φ) = −
n∑
i=1
wi
yi − p∑
j=1
xijbj
2 ,
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where wi = 1/
(
µˆi + φµˆ
2
i
)
, and µˆi is the estimate of µi in the previous iteration. Then to
solve b, we just need to solve the following penalized least squares problem.
n∑
i=1
wi
yi − p∑
j=1
xijbj
2 + p∑
j=1
q(bj),
subject to the constraints of bj ≥ 0 for 1 ≤ j ≤ J . We employ a modified Iterative Adap-
tive Lasso (IAL) algorithm Sun et al. [2010] to solve this problem. Given estimates of bj
(1 ≤ j ≤ p), φ can be re-estimated by maximizing the conditional likelihood of φ.
Specifically, the implementation includes the following four levels of loops:
• outer loop: Iterate across all combinations of tuning parameter λn and τn.
• middle loop 1: This corresponds to the loop of iteratively update bj (1 ≤ j ≤ p)
and φ. For each given φ, we carry out the next two nested loops to estimate bj and
then re-estimate φ.
• middle loop 2: This corresponds to the loop of IRLS (Iterative Re-weighted Least
Squares). Update the quadratic approximation lQ using current estimate of bj (1 ≤
j ≤ p) and φ.
• inner loop: Run the modified IAL to re-estimate bj (1 ≤ j ≤ p) on the penalized
weighted least squares problem.
The modified IAL algorithm is as follows. It is different from the IAL Sun et al.
[2010] in that the regression coefficients need to be non-negative and we remove the step
of estimating residual variance to improve the computational efficiency and robustness.
1. Initialization: initialize bj with zero’s or estimate from previous IRLS iteration,
and initialize κj = (bj + τ)/λ, where 1 ≤ j ≤ p.
2. Iterative Updates:
(a) For j = 1, ..., p, update bj ,{
bj = b¯j − 1/κj if b¯j > 1/κj
bj = 0 otherwise
,
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where
b¯j =
(
n∑
i=1
x2ij
)−1 n∑
i=1
xij
yi −∑
k 6=j
xikbk
 .
(b) Update κj : κj = (bj + τ)/λ.
This IAL algorithm is converged if the coefficient estimates bˆ1, ..., bˆp have little change.
Tuning parameter selection is a crucial step for any penalization method. We select the
tuning parameters λ and τ by a two-dimensional grid search. By default, we search across
10 values of λ and 3 values of τ , which are 30 tuning parameter combinations. Larger λ
and smaller τ leads to stronger penalty, and thus we first choose the ratio λ/τ ’s so that
they are uniformly distributed in log scale and the largest λ/τ is large enough to penalize
all coefficients to 0. Then τ ’s are chosen so that they are uniformly distributed in log scale
with largest τ being 0.1. Finally for each ratio r = λ/τ and for each τ , λ can be calculated
as rτ . Simulations show that the results are similar if we carry out grid search for 500 or
50 tuning parameter combinations.
Through the two-dimensional grid search, we choose the combination of λ and τ that
minimizes BIC or extended BIC ? if n > p or n ≤ p, respectively. If we only study the
expression of known RNA isoforms, p is often smaller than n (e.g., see Supplementary
Figure 4), and thus BIC is used. In contrast, if we detect de novo RNA isoforms, p is
often larger than n (e.g., see Supplementary Figure 5), and thus extended BIC is used. For
hypothesis testing of the isoform usage, the rule (BIC or extended BIC) is chosen based
on the alternative model and the same rule is applied to the null model. More specifically,
BIC is defined as
BIC = −2l(Θˆ) + s log(n),
where l(Θˆ) is log likelihood given parameter estimates Θˆ, s is the number of non-zero
coefficients after variable selection, and n is sample size. Following Chen and Chen (2012)
?, the extended BIC is defined as
extBIC = −2l(Θˆ) + s log(n) + 2γ log p,
where 0 ≤ γ < 1− 1/(2κ) given p = O(nκ). In our simulation and real data studies, since
we restrict the number of covariates p ≤ 10n, we set κ = 1 and choose γ = 1/2. Tuning
parameter selection is an active research area and we do not claim our approach is optimal.
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However our hypothesis-testing framework rely on parametric bootstrap to resample RNA-
seq read counts to calculate p-values. This resampling-based p-value calculation is robust
to bias due to suboptimal tuning parameters because any bias that influences the null
distribution of the test statistic can be captured through resampling. On the other hand,
optimal tuning parameter selection may improve the power of our method.
D Mouse haploperidol treatment experiment
Ethics Statement. All animal work was conducted in compliance with the “Guide for
the Care and Use of Laboratory Animals” (Institute of Laboratory Animal Resources, Na-
tional Research Council, 1996) and approved by the Institutional Animal Care and Use
Committee of the University of North Carolina.
Animals. The mice used in this study were N=2 inbred C57BL/6J females (one placebo
treated, one drug treated) and N=2 (129S1Sv/ImJ x PWK/PhJ)F1 females (one placebo
treated, one drug treated). All animals were bred at UNC from mice that were less than
6 generations removed from founders acquired from the Jackson Laboratory (Bar Harbor,
ME). Animals were maintained on a 14 hour light, 10 hour dark schedule with lights on at
0600. The housing room was maintained at 20-24C with 40-50% relative humidity. Mice
were housed in standard 20cm × 30cm ventilated polysulfone cages with laboratory grade
Bed-O-Cob bedding. Water and Purina Prolab RMH3000 were available ad libitum. A
small section of PVC pipe was present in each cage for enrichment.
Drug treatment. Slow release haloperidol pellets (3.0 mg/kg/day; Innovative Research
of America; Sarasota, FL)? were implanted subcutaneously with a trocar at 8 weeks of
age. Blood plasma was collected via tail nick for a drug concentration assay after 30 days
of exposure to haloperidol. Steady-state concentration of haloperidol within the clinically
relevant range (10-50 nanomoles/L, nM, or 3.75-19 ng/ml)? was achieved for both drug
treated animals (C57BL/6J: 19nM, (129S1Sv/ImJ x PWK/PhJ)F1: 24 nM).
Tissue collection. Mice were sacrificed at 12 weeks of age (following 30 days of drug
or placebo treatment) by cervical dislocation without anesthesia to avoid its confounding
effects on gene expression. Mice were removed from their home cages at 9:00 AM and sac-
rificed between 10:00 AM and 12:00 PM. Whole brain was rapidly collected, snap frozen
in liquid nitrogen, and pulverized to a fine powder using a BioPulverizer unit (BioSpec
Products, Bartlesville, OK).
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RNA extraction. Total RNA was extracted from ∼25 mg of tissue powder using auto-
mated instrumentation (Maxwell 16 Tissue LEV Total RNA Purification Kit, Promega,
Madison, WI). RNA concentration was measured by fluorometry (Qubit 2.0 Fluorometer,
Life Technologies Corp., Carlsbad, CA) and RNA quality was verified using a microfluidics
platform (Bioanalyzer, Agilent Technologies, Santa Clara, CA).
RNAseq methods. A multiplex library containing all four samples was prepared us-
ing the Illumina (San Diego, CA) TruSeq mRNA Sample Preparation Kit v2 with unique
indexed adapters (GCCAAT, ACAGTG, CTTGTA, CAGATC). One microgram of total
RNA per sample was used as input and the resulting libraries were quantitated using fluo-
rometry. An Illumina HiSeq 2000 instrument was used to generate 100bp paired-end reads
(2x100) in one lane of a flow cell.
For the C57BL/6J inbred mice, the mm9 reference was used for alignment. For the
F1 animals, we developed a customized RNAseq alignment pipeline tailored to this experi-
ment. Our approach considered these mice as diploid and included two separate alignments
that were subsequently merged. This has the advantage of incorporating all known strain-
specific genetic variants into the alignment reference sequence to improve alignment quality
and to minimize bias caused by differences in genetic distance between the parental genomes
to the reference sequence. First, reads from the F1 hybrids were aligned to the appropriate
’pseudogenomes’ representing each of the parental genomes using TopHatTrapnell et al.
[2009] (v1.4, default parameters including segment length 25 bp, 2 mismatches allowed per
segment, 2 mismatches total allowed per 100 bp read, and maximum indel of 3 bases).
Pseudogenomes are approximations constructed by incorporating all known SNPs and in-
dels into the C57BL/6 genome (mm9)?. We included all variants reported by a large-scale
sequencing effort that included 129S1Sv/ImJ and PWK/PhJKeane et al. [2011] (June 2011
release). Second, we mapped coordinates from the pseudogenome aligned reads to mm9
coordinates. This involved updating the alignment positions and rewriting the CIGAR
strings of each aligned read?. This was necessary as indels alter the pseudogenome coordi-
nates relative to mm9. Third, we annotated each aligned read to indicate the numbers of
maternal and paternal alleles (SNPs and indels) observed in a given read and its paired-end
mate. Considering the paired-end mates allowed the use of more paired-end reads for ASE.
Finally, alignments to maternal and paternal pseudogenomes were merged by computing
the proper union of the separate alignments (i.e., the two alignments were combined such
that a read aligning to the same position in both alignments was counted once).
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E Massively Parallel Computing for IsoDetector
In practice, the penalized estimation in IsoDetector is performed on a grid of λ and
τ and the best estimate is chosen according to certain model selection criterion such as
BIC. For hypothesis testing purpose, this tuning process has to be done on thousands
of bootstrap samples for each gene, which incurs formidable computation burden in real
applications. Massively parallel computing based on graphical processing units (GPUs)
provides a promising solution. However the coordinate descent based algorithm does not
particularly suit the massively parallel computing architecture. Here we propose an algo-
rithm based on the minorization-maximization (MM) principle. Like EM algorithm, MM
algorithm always increases the objective value and thus is numerically stable. Furthermore,
MM algorithm tends to separate variables, making massively parallel computing feasible
in high dimensional optimization problems ?.
Consider the log likelihood of a negative binomial model with response vector y ∈ Nn
and design matrix X ∈ Rn×p
`(b, φ|y,X) =
n∑
i=1
[
log
(φ−1)(yi)
yi!
+ yi log(φx
T
i b)− (yi + φ−1) log(1 + φxTi b)
]
,
where φ is the overdispersion parameter of negative binomial distribution, and (φ−1)(yi)
denotes the rising factorial
∏yi−1
k=0 (φ
−1 + k) = φ−1(φ−1 + 1)...(φ−1 + yi − 1). We assume
that entries of X are nonnegative which is true for isoform estimation problem. To simul-
taneously achieve isoform selection and estimation, IsoDetector relies on log penalized
estimation due to its attractive properties. In particular we seek to maximize the penalized
objective function
f(b, φ) = `(b, φ | y,X)−
p∑
j=1
λ log(bj + τ), (14)
where λ and τ are two tuning parameters, subject to the nonnegativity constraint bj ≥ 0.
The derivation of MM algorithm for maximizing (14) relies on simple inequalities ?.
The strategy is to minorize term by term. By concavity of log function,
log(xTi b) = log
∑
j
xijb
(t)
j
 ≥∑
j
w
(t)
ij log bj + c
(t),
35
where the superscript t indicates iteration number and c(t) is a constant irrelevant to
optimization, and
w
(t)
ij =
xijb
(t)
j∑
j xijb
(t)
j
.
By the convexity of negative log function, we apply supporting hyperplane inequality to
obtain minorizations
− log(1 + φxTi b) ≥ −
φxTi b
1 + φxTi b
(t)
+ c(t)
− log(bj + τ) ≥ − bj
b
(t)
j + τ
+ c(t).
Combining above pieces, we obtain an overall minorization function to the objective func-
tion (14)
g(b|b(t), φ(t))
=
n∑
i=1
yi∑
j
w
(t)
ij log bj −
(
yi + (φ
(t))−1
1 + φ(t)xTi b
(t)
)
φ(t)
∑
j
xijbj
− λ∑
j
bj
b
(t)
j + τ
+ c(t)
=
∑
j
[(∑
i
yiw
(t)
ij
)
log bj −
(∑
i
xij(yiφ
(t) + 1)
1 + φ(t)xTi b
(t)
+
λ
b
(t)
j + τ
)
bj
]
+ c(t).
It is easy to check that
g(b|b(t), φ(t)) ≤ f(b, φ) for all b
g(b(t)|b(t), φ(t)) = f(b(t), φ(t)).
Therefore maximizing the minorizing function g(b|b(t), φ(t)) always increases the objective
function
f(b(t+1), φ(t)) ≥ g(b(t+1)|b(t), φ(t)) ≥ g(b(t)|b(t), φ(t)) = f(b(t), φ(t)).
Setting derivative of g(b|b(t), φ(t)) to zero yields an extremely simple update
b
(t+1)
j =
∑
i yiw
(t)
ij∑
i
xij(yiφ(t)+1)
1+φ(t)xTi b
(t)
+ λ
b
(t)
j +τ
, j = 1, . . . , p, (15)
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involving only trivial algebra. All parameters bj are separated and thus updated simulta-
neously, matching perfectly with the massively parallel architecture of GPUs. The nonneg-
ativity constraints bj ≥ 0 are also preserved in the update (15). Whenever b(0)j are positive,
all subsequent iterates b
(t)
j will always be nonnegative. Effects of the tuning parameters λ
and τ are clear: large λ and small τ cause more shrinkage and vice versa. Furthermore,
the log penalty penalizes small bj more heavily than large bj , a desired property the lasso
penalty lacks.
The update (15) always increases the objective value. However, it does not update the
overdispersion parameter φ. In practice, we update φ after every a few (e.g., five) updates
of b by (15). Updating of φ can be done by either Newton’s steps or by invoking MM
algorithm again. Both are simple because it is a smooth univariate optimization problem.
For brevity the details are omitted here.
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F Supplementary Figures
(a) (b)
Set1:Chr1
Set1:Chr18
Set2:Chr1
Set2:Chr18
Case:Chr1
Control:Chr1
Case:Chr18
Control:Chr18
(c)total counts per transcript cluster isoform usage per transcript
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Figure S2: A summary of simulated data. We first simulated ∼2 million 76+76bps
paired-end reads for data set 1 and data set 2, based on the transcriptome annotation
of chromosome 1 and 18 of mouse genome. The expression of any gene/transcript are
independent between data set 1 and data set 2. Then as illustrated in (a), a case and a
control sample were generated as follows. For chromosome 1, the sequence fragments of
simulation set 1 were randomly split into the case and control samples. For chromosome 18,
half of the sequence fragments from set 1 were selected for case and half of the sequence
fragments from set 2 were selected for control. Therefore, comparing case and control,
all the transcripts in chromosome 1 were equivalently expressed and all the transcripts
in chromosome 18 were differentially expressed, either in terms of total expression (b)
or isoform usage (c). (a) Comparison of the total number of fragments per transcript
cluster between the case and the control samples. (c) Comparison of isoform usage of each
transcript between the case and the control samples. Here isoform usage is quantified by
the ratio of the number of sequence fragments of one transcript over the total number of
fragments of the corresponding transcript cluster.
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Figure S3: Upper panel shows the distribution of the lengths of non-overlapping exons.
Lower panel shows the distribution of the number of exons overlapped by each paired end
read. A paired-end read overlaps an exon if at least one base pair of either end of the read
overlap with the exon. About 46%, 27%, and 18% of the reads overlap with only one, two,
or three exons.
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Figure S4: The relation between the effective length of an exon set (divided by the total
effective length of the transcript cluster to which the exon belongs) and the proportion of
RNA-seq fragments mapped to this exon set in our simulated data. The correlation between
them is 0.88. Because different transcript clusters have different expression abundance,
we compared read count and effective length as the proportions over the corresponding
transcript cluster. Note that the effective length is calculated while assuming all the exons
in an exon set are contiguous, which may not be true. Therefore the results here can only
be viewed as an approximation.
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Figure S5: An illustration of the dimension of the isoform selection problem when we
use known transcriptome annotation. For each transcript cluster, we consider a variable
selection problem where sample size n is the number of expressed exon sets, and the number
of covariates p is the number of (candidate) isoforms. The solid line indicates p = n.
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Figure S6: An illustration of the dimension of the isoform selection problem when there is
no isoform annotation. For each gene (or transcript cluster), we consider a variable selection
problem where sample size n is the number of expressed exon sets, and the number of
covariates p is the number of (candidate) isoforms. The solid line indicates p = n, and the
broken line indicates p = 10n. In our implementation, we choose the number of candidate
isoforms so that p ≤ 10n approximately. Users can loose this restriction with price of
increasing computational cost. Our experience is that IsoDetector runs well for p ≤ 100n.
42
Figure S7: An illustration of the correlation among the isoforms of each transcript cluster
when we use known isoform annotation. Each point indicates a transcript cluster where
x-axis is the number of isoforms and y-axis is the proportion of variance explained by the
first principal component.
43
Figure S8: An illustration of the correlation among the isoforms of each transcript cluster
when there is no isoform annotation. Each point indicates a transcript cluster where x-axis
is the number of isoforms and y-axis is the proportion of variance explained by the first
principal component.
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Figure S9: An illustration of the number of isoforms selected by IsoDetector when we
choose the candidate isoforms based on the known isoform annotation.
45
Figure S10: An illustration of the number of isoforms selected by IsoDetector when we
choose the candidate isoforms without using any isoform annotation.
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Figure S11: Compare the type I error of IsoDOT and Cuffdiff2 for detesting genes with
differential isoform usage (a-b) or differential expression (c-d), while transcriptome annota-
tion is known (a,c) or not (b,d). For the case of differential isoform usage, cufflinks provides
results for “isoform” and “promoter”, where the former is for isoform sharing a TSS, and
the latter is for differential usage of TSSs. For the “isoform” case, we have collapsed the
p-values of multiple tests of a gene by taking minimum, thus it leads to an over-estimate
of type I error.
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Figure S12: Compare the results of IsoDOT and Cuffdiff2 by ROC curves. The ROC
curves compare two methods across a wide range of p-value cutoffs. If one method has a
calibration issue (e.g., p-value is larger than it should be) but still ranks the genes correctly,
it would perform well judged by ROC curve. The results shown here demonstrate that the
IsoDOT still performs better than Cuffdiff2 even if we allow the results of Cuffdiff2 to be
calibrated.
IsoDOT_knownIso_DE+DU_top100_DAVID
Annotation Clu ter 1 Enrichment Score: 1.946759207114314
Category Term Count List Total Pop Hits Pop Total Bonferroni Benjamini FDR
GOTERM_BP_FAT GO:0006470~protein amino acid dephosphorylation 5 75 114 13588 9.18E-01 7.14E-01 5.09259555
GOTERM_BP_FAT GO:0016311~dephosphorylation 5 75 141 13588 9.95E-01 5.88E-01 10.5009295
GOTERM_MF_FAT GO:0004721~phosphoprotein phosphatase activity 5 74 152 13288 8.95E-01 0.31363415 11.786371
GOTERM_MF_FAT GO:0004725~protein tyrosine phosphatase activity 4 74 101 13288 9.85E-01 0.29586889 20.8469542
GOTERM_MF_FAT GO:0016791~phosphatase activity 5 74 238 13288 1.00E+00 0.46048401 42.2094889
IsoDOT_knownIso_DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 5.099005725187938
Category Term Count List Total Pop Hits Pop Total Bonferroni Benjamini FDR
GOTERM_CC_FAT GO:0043005~neuron projection 12 71 245 12504 1.78E-05 1.78E-05 1.25E-04
GOTERM_CC_FAT GO:0042995~cell projection 14 71 575 12504 2.66E-03 8.88E-04 0.01866466
GOTERM_CC_FAT GO:0030424~axon 6 71 107 12504 5.53E-02 0.01412245 0.39776375
IsoDOT_unknownIso_DE+DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 2.67804567502071
Category Term Count List Total Pop Hits Pop Total Bonferroni Benjamini FDR
GOTERM_CC_FAT GO:0000267~cell fraction 12 84 596 12504 2.74E-01 0.27418878 2.26260365
GOTERM_CC_FAT GO:0005624~membrane fraction 11 84 510 12504 2.85E-01 0.15426318 2.36465753
GOTERM_CC_FAT GO:0005626~insoluble fraction 11 84 528 12504 3.51E-01 0.13405492 3.0366353
IsoDOT_unknownIso_DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.2354810652684654
Category Term Count List Total Pop Hits Pop Total Bonferroni Benjamini FDR
GOTERM_BP_FAT GO:0055114~oxidation reduction 7 43 672 13588 9.98E-01 0.99833419 20.5444102
SP_PIR_KEYWORDS nadp 3 63 142 17854 1.00E+00 0.89604092 65.1478962
SP_PIR_KEYWORDS oxidoreductase 5 63 572 17854 1.00E+00 0.92661226 81.7806757
Figure S13: DAVID functional category enrichments for DIU genes (with transcriptome
annotation).
IsoDOT_knownIso_DE+DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.946759207114314
Category Term Count List Total Pop Hits Pop Total Bonferroni Benjamini FDR
GOTERM_BP_FAT GO:0006470~protein amino acid dephosphorylation 5 75 114 13588 9.18E-01 7.14E-01 5.09259555
163 1 dephosphorylation 5 75 141 5 5. 8E-01 1 009295
GOTE M_MF_FAT GO:0004721~phosphoprotein phosphatase activity 5 74 5 3288 8.95E- 1 31363415 11.786371
GOTE M_MF_FAT GO:0004725~protein tyrosine phosphatase activity 4 74 101 3288 9.85E- 1 29586889 20 8469542
GOTERM_MF_FAT GO:0016791~phosphatase activity 5 74 238 13288 1.00E+00 0.46048401 42.2094889
IsoDOT_knownIso_DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 5.099005725187938
Category Term Count List Total Pop Hits Pop Total Bonferroni Benjamini FDR
GOTERM_CC_FAT GO:0043005~neuron projection 12 71 245 12504 1.78E-05 1.78E-05 1.25E-04
GOTERM_CC_FAT GO:0042995~cell projection 14 71 575 12504 2.66E-03 8.88E-04 0.01866466
GOTERM_CC_FAT GO:0030424~axon 6 71 107 12504 5.53E-02 0.01412245 0.39776375
IsoDOT_unknownIso_DE+DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 2.67804567502071
Category Term Count List Total Pop Hits Pop Total Bonferroni Benjamini FDR
GOTERM_CC_FAT GO:0000267~cell fraction 12 84 596 12504 2.74E-01 0.27418878 2.26260365
GOTERM_CC_FAT GO:0005624~membrane fraction 11 84 510 12504 2.85E-01 0.15426318 2.36465753
GOTERM_CC_FAT GO:0005626~insoluble fraction 11 84 528 12504 3.51E-01 0.13405492 3.0366353
IsoDOT_unknownIso_DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.2354810652684654
Category Term Count List Total Pop Hits Pop Total Bonferroni Benjamini FDR
GOTERM_BP_FAT GO:0055114~oxidation reduction 7 43 672 13588 9.98E-01 0.99833419 20.5444102
SP_PIR_KEYWORDS nadp 3 63 142 17854 1.00E+00 0.89604092 65.1478962
SP_PIR_KEYWORDS oxidoreductase 5 63 572 17854 1.00E+00 0.92661226 81.7806757
Figure S14: DAVID functional category enrichments for DIE genes (with transcriptome
annotation).
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IsoDOT_knownIso_DE+DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.946759207114314
Category Term Count List Total Pop Hits Pop Total Bonferroni
GOTERM_BP_FAT GO:0006470~protein amino acid dephosphorylation 5 75 114 13588 9.18E-01
GOTERM_BP_FAT GO:0016311~dephosphorylation 5 75 141 13588 9.95E-01
GOTERM_MF_FAT GO:0004721~phosphoprotein phosphatase activity 5 74 152 13288 8.95E-01
GOTERM_MF_FAT GO:0004725~protein tyrosine phosphatase activity 4 74 101 13288 9.85E-01
GOTERM_MF_FAT GO:0016791~phosphatase activity 5 74 238 13288 1.00E+00
IsoDOT_knownIso_DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 5.099005725187938
Category Term Count List Total Pop Hits Pop Total Bonferroni
GOTERM_CC_FAT GO:0043005~neuron projection 12 71 245 12504 1.78E-05
GOTERM_CC_FAT GO:0042995~cell projection 14 71 575 12504 2.66E-03
GOTERM_CC_FAT GO:0030424~axon 6 71 107 12504 5.53E-02
IsoDOT_unknownIso_DE+DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.6629495798638765
Category Term Count List Total Pop Hits Pop Total Bonferroni
GOTERM_BP_FAT GO:0016477~cell migration 6 76 240 13588 9.99E-01
GOTERM_BP_FAT GO:0051674~localization of cell 6 76 284 13588 1.00E+00
GOTERM_BP_FAT GO:0048870~cell motility 6 76 284 13588 1.00E+00
GOTERM_BP_FAT GO:0006928~cell motion 6 76 367 13588 1.00E+00
IsoDOT_unknownIso_DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.3384615631131074
Category Term Count List Total Pop Hits Pop Total Bonferroni
GOTERM_MF_FAT GO:0030955~potassium ion binding 5 65 118 13288 3.77E-01
GOTERM_BP_FAT GO:0006813~potassium ion transport 5 68 160 13588 9.97E-01
GOTERM_MF_FAT GO:0005249~voltage-gated potassium channel activity 4 65 99 13288 9.00E-01
GOTERM_BP_FAT GO:0015672~monovalent inorganic cation transport 6 68 303 13588 1.00E+00
GOTERM_MF_FAT GO:0031420~alkali metal ion binding 5 65 206 13288 9.64E-01
GOTERM_MF_FAT GO:0022843~voltage-gated cation channel activity 4 65 128 13288 9.90E-01
Figure S15: DAVID functional category enrichments for DIU genes (without transcriptome
annotation).
IsoDOT_knownIso_DE+DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.946759207114314
Category Term Count List Total Pop Hits Pop Total Bonferroni
GOTERM_BP_FAT GO:0006470~protein amino acid dephosphorylation 5 75 114 13588 9.18E-01
GOTERM_BP_FAT GO:0016311~dephosphorylation 5 75 141 13588 9.95E-01
GOTERM_MF_FAT GO:0004721~phosphoprotein phosphatase activity 5 74 152 13288 8.95E-01
GOTERM_MF_FAT GO:0004725~protein tyrosine phosphatase activity 4 74 101 13288 9.85E-01
GOTERM_MF_FAT GO:0016791~phosphatase activity 5 74 238 13288 1.00E+00
IsoDOT_knownIso_DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 5.099005725187938
Category Term Count List Total Pop Hits Pop Total Bonferroni
GOTERM_CC_FAT GO:0043005~neuron projection 12 71 245 12504 1.78E-05
GOTERM_CC_FAT GO:0042995~cell projection 14 71 575 12504 2.66E-03
GOTERM_CC_FAT GO:0030424~axon 6 71 107 12504 5.53E-02
IsoDOT_unknownIso_DE+DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.6629495798638765
Category Term Count List Total Pop Hits Pop Total Bonferroni
GOTERM_BP_FAT GO:0016477~cell migration 6 76 240 13588 9.99E-01
GOTERM_BP_FAT GO:0051674~localization of cell 6 76 284 13588 1.00E+00
GOTERM_BP_FAT GO:0048870~cell motility 6 76 284 13588 1.00E+00
GOTERM_BP_FAT GO:0006928~cell motion 6 76 367 13588 1.00E+00
IsoDOT_unknownIso_DU_top100_DAVID
Annotation Cluster 1 Enrichment Score: 1.3384615631131074
Category Term Count List Total Pop Hits Pop Total Bonferroni
GOTERM_MF_FAT GO:0030955~potassium ion binding 5 65 118 13288 3.77E-01
GOTERM_BP_FAT GO:0006813~potassium ion transport 5 68 160 13588 9.97E-01
GOTERM_MF_FAT GO:0005249~voltage-gated potassium channel activity 4 65 99 13288 9.00E-01
GOTERM_BP_FAT GO:0015672~monovalent inorganic cation transport 6 68 303 13588 1.00E+00
GOTERM_MF_FAT GO:0031420~alkali metal ion binding 5 65 206 13288 9.64E-01
GOTERM_MF_FAT GO:0022843~voltage-gated cation channel activity 4 65 128 13288 9.90E-01
Figure S16: DAVID func ional category enrichments for DIE genes (without transcriptome
annotation).
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cuffdiff_knownIso_promoter_top100_DAVID
Category Term Count List0Total Pop0Hits Pop0Total Bonferroni
GOTERM_MF_FAT GO:0003677~DNA0binding 21 76 1781 13288 2.7EM01
GOTERM_BP_FAT GO:0045449~regulation0of0transcription 21 69 2227 13588 9.5EM01
GOTERM_BP_FAT GO:0006350~transcription 18 69 1772 13588 9.6EM01
GOTERM_MF_FAT GO:0003700~transcription0factor0activity 11 76 776 13288 8.9EM01
GOTERM_BP_FAT GO:0006355~regulation0of0transcription,0DNAMdependent 15 69 1465 13588 1.0E+00
GOTERM_BP_FAT GO:0051252~regulation0of0RNA0metabolic0process 15 69 1488 13588 1.0E+00
cuffdiff_knownIso_splicing_top100_DAVID
Category Term Count List0Total Pop0Hits Pop0Total Bonferroni
GOTERM_BP_FAT GO:0006650~glycerophospholipid0metabolic0process 4 67 88 13588 1.0E+00
GOTERM_BP_FAT GO:0046486~glycerolipid0metabolic0process 4 67 129 13588 1.0E+00
GOTERM_BP_FAT GO:0030384~phosphoinositide0metabolic0process 3 67 63 13588 1.0E+00
GOTERM_BP_FAT GO:0006644~phospholipid0metabolic0process 4 67 163 13588 1.0E+00
GOTERM_BP_FAT GO:0019637~organophosphate0metabolic0process 4 67 176 13588 1.0E+00
cuffdiff_unknownIso_promoter_top100_DAVID
Category Term Count List0Total Pop0Hits Pop0Total Bonferroni
GOTERM_MF_FAT GO:0005083~small0GTPase0regulator0activity 7 75 223 13288 2.7EM01
GOTERM_BP_FAT GO:0051336~regulation0of0hydrolase0activity 6 69 196 13588 8.0EM01
GOTERM_MF_FAT GO:0005099~Ras0GTPase0activator0activity 4 75 65 13288 7.0EM01
GOTERM_BP_FAT GO:0043087~regulation0of0GTPase0activity 4 69 93 13588 1.0E+00
GOTERM_BP_FAT GO:0046578~regulation0of0Ras0protein0signal0transduction 5 69 181 13588 1.0E+00
GOTERM_MF_FAT GO:0030695~GTPase0regulator0activity 7 75 361 13288 9.6EM01
cuffdiff_unknownIso_splicing_top100_DAVID
Category Term Count List0Total Pop0Hits Pop0Total Bonferroni
GOTERM_BP_FAT GO:0000902~cell0morphogenesis 6 63 309 13588 1.0E+00
GOTERM_BP_FAT GO:0048858~cell0projection0morphogenesis 5 63 202 13588 1.0E+00
GOTERM_BP_FAT GO:0030030~cell0projection0organization 6 63 319 13588 1.0E+00
GOTERM_BP_FAT GO:0032990~cell0part0morphogenesis 5 63 212 13588 1.0E+00
GOTERM_BP_FAT GO:0032989~cellular0component0morphogenesis 6 63 351 13588 1.0E+00
GOTERM_BP_FAT GO:0048812~neuron0projection0morphogenesis 4 63 176 13588 1.0E+00
Figure S17: DAVID functional category enrichments for the results from Cuffldiff.
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Figure S18: Differential isoform usage of gene Grin2b between two C57BL/6 mice with
haloperidal or placebo treatment. Note Grin2b belongs to a transcript cluster with four
genes. However, the other three genes are short and contribute little if any signal of
differential isoform usage.
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Figure S19: Change of overt chewing movements for three inbred strains between day 0
and day 30 after haloperidol treatment. See Crowley et al. Crowley et al. [2012] for more
details of the experiment and the results of other phenotypic outcomes.
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Figure S20: An example to show that negative binomial distribution can provide ade-
quate fit to RNA-seq fragment count data whereas Poisson distribution assumption leads
to severe underestimate of variance. The RNA-seq data used in this example are the
RNA-seq fragment count for gene VPRBP (Vpr (HIV-1) binding protein, ensembl ID:
ENSG00000145041) from 50 HapMap CEU samples ?. The MLE of the two distribu-
tions were obtained using R function glm and glm.nb, respectively, after correction for
read-depth.
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Figure S21: Compare type I error and power when we use the Lasso penalty or the Log
penalty in IsoDOT. (a) Type I for DIU test. (b) Type I error for DIE test. (c) Power for
DIU test. (d) Power for DIE test. In panel (a) and (b), the y-axis is type I error ratio,
which is the ratio of observed type I error rate divided by the corresponding p-value cutoff
(x-axis), which is the expected type I error rate.
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Table S1: Read depth of the RNA-seq data in mouse haloperidol treatment study. Each
sequence fragment was sequenced on both ends by 93-100bp. The first four rows show the
information of four mince and the last four rows are for allele-specific RNA-seq reads from
the two F1 mice.
Sample Genetic Treatment Total number Number of fragments
ID background of mapped reads passed QC and mapped
to exonic regions
BB1050 C57BL/6J placebo 21,482,924 8,337,872
BB1068 C57BL/6J haloperidol 27,178,749 10,486,170
CG0069 129×PWK placebo 24,014,041 10,476,460
CG0077 129×PWK haloperidol 20,365,336 8,871,864
CG0069 129 @ 129×PWK placebo 4,667,545 1,953,335
CG0069 PWK @ 129×PWK placebo 4,605,879 1,931,791
CG0077 129 @ 129×PWK haloperidol 3,993,348 1,668,243
CG0077 PWK @ 129×PWK haloperidol 3,957,371 1,654,705
Table S2: Top 100 genes identified from differential isoform
usage (DU only) analysis comparing two C57BL/6J mice with
haloperidol or placebo treatments.
Ensembl ID symbol name
ENSMUSG00000040537 Adam22 a disintegrin and metallopeptidase domain 22
ENSMUSG00000020431 Adcy1 adenylate cyclase 1
ENSMUSG00000049470 Aff4 AF4/FMR2 family, member 4
ENSMUSG00000061603 Akap6 A kinase (PRKA) anchor protein 6
ENSMUSG00000040407 Akap9 A kinase (PRKA) anchor protein (yotiao) 9
ENSMUSG00000069601 Ank3 ankyrin 3, epithelial
ENSMUSG00000071176 Arhgef10 Rho guanine nucleotide exchange factor (GEF) 10
ENSMUSG00000059495 Arhgef12 Rho guanine nucleotide exchange factor (GEF) 12
ENSMUSG00000002343 Armc6 armadillo repeat containing 6
ENSMUSG00000020788 Atp2a3 ATPase, Ca++ transporting, ubiquitous
ENSMUSG00000003604 Aven apoptosis, caspase activation inhibitor
ENSMUSG00000048251 Bcl11b B-cell leukemia/lymphoma 11B
Continued on next page
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Table S2 – Continued from previous page
Ensembl ID symbol name
ENSMUSG00000049658 Bdp1 B double prime 1, subunit of RNA polymerase III tran-
scription initiation factor IIIB
ENSMUSG00000042460 C1galt1 core 1 synthase, glycoprotein-N-acetylgalactosamine 3-
beta-galactosyltransferase, 1
ENSMUSG00000039983 Ccdc32 coiled-coil domain containing 32
ENSMUSG00000033671 Cep350 centrosomal protein 350
ENSMUSG00000021097 Clmn calmin
ENSMUSG00000060924 Csmd1 CUB and Sushi multiple domains 1
ENSMUSG00000048796 Cyb561d1 cytochrome b-561 domain containing 1
ENSMUSG00000017999 Ddx27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27
ENSMUSG00000037426 Depdc5 DEP domain containing 5
ENSMUSG00000024456 Diap1 diaphanous homolog 1 (Drosophila)
ENSMUSG00000045103 Dmd dystrophin, muscular dystrophy
ENSMUSG00000041268 Dmxl2 Dmx-like 2
ENSMUSG00000039716 Dock3 dedicator of cyto-kinesis 3
ENSMUSG00000036270 Edc4 enhancer of mRNA decapping 4
ENSMUSG00000028760 Eif4g3 eukaryotic translation initiation factor 4 gamma, 3
ENSMUSG00000039167 Eltd1 EGF, latrophilin seven transmembrane domain contain-
ing 1
ENSMUSG00000004267 Eno2 enolase 2, gamma neuronal
ENSMUSG00000032314 Etfa electron transferring flavoprotein, alpha polypeptide
ENSMUSG00000010517 Faf1 Fas-associated factor 1
ENSMUSG00000025262 Fam120c family with sequence similarity 120, member C
ENSMUSG00000025153 Fasn fatty acid synthase
ENSMUSG00000070733 Fryl furry homolog-like (Drosophila)
ENSMUSG00000039801 Gm5906 RIKEN cDNA 2410089E03 gene
ENSMUSG00000031210 Gpr165 G protein-coupled receptor 165
ENSMUSG00000020176 Grb10 growth factor receptor bound protein 10
ENSMUSG00000030209 Grin2b glutamate receptor, ionotropic, NMDA2B (epsilon 2)
ENSMUSG00000031584 Gsr glutathione reductase
ENSMUSG00000006930 Hap1 huntingtin-associated protein 1
ENSMUSG00000029104 Htt huntingtin
ENSMUSG00000009828 Ick intestinal cell kinase
ENSMUSG00000023830 Igf2r insulin-like growth factor 2 receptor
Continued on next page
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Table S2 – Continued from previous page
Ensembl ID symbol name
ENSMUSG00000042599 Jhdm1d jumonji C domain-containing histone demethylase 1 ho-
molog D (S. cerevisiae)
ENSMUSG00000024410 K100 RIKEN cDNA 3110002H16 gene
ENSMUSG00000016946 Kctd5 potassium channel tetramerisation domain containing 5
ENSMUSG00000063077 Kif1b kinesin family member 1B
ENSMUSG00000027550 Lrrcc1 leucine rich repeat and coiled-coil domain containing 1
ENSMUSG00000028649 Macf1 microtubule-actin crosslinking factor 1
ENSMUSG00000036278 Macrod1 MACRO domain containing 1
ENSMUSG00000008763 Man1a2 mannosidase, alpha, class 1A, member 2
ENSMUSG00000059474 Mbtd1 mbt domain containing 1
ENSMUSG00000020184 Mdm2 transformed mouse 3T3 cell double minute 2
ENSMUSG00000024294 Mib1 mindbomb homolog 1 (Drosophila)
ENSMUSG00000038056 Mll3 myeloid/lymphoid or mixed-lineage leukemia 3
ENSMUSG00000022889 Mrpl39 mitochondrial ribosomal protein L39
ENSMUSG00000033004 Mycbp2 MYC binding protein 2
ENSMUSG00000030739 Myh14 myosin, heavy polypeptide 14
ENSMUSG00000034593 Myo5a myosin VA
ENSMUSG00000027799 Nbea neurobeachin
ENSMUSG00000020716 Nf1 neurofibromatosis 1
ENSMUSG00000038495 Otud7b OTU domain containing 7B
ENSMUSG00000021140 Pcnx pecanex homolog (Drosophila)
ENSMUSG00000002265 Peg3 paternally expressed 3
ENSMUSG00000028085 Pet112l PET112-like (yeast)
ENSMUSG00000039943 Plcb4 phospholipase C, beta 4
ENSMUSG00000032827 Ppp1r9a protein phosphatase 1, regulatory (inhibitor) subunit 9A
ENSMUSG00000038976 Ppp1r9b protein phosphatase 1, regulatory subunit 9B
ENSMUSG00000003099 Ppp5c protein phosphatase 5, catalytic subunit
ENSMUSG00000039410 Prdm16 PR domain containing 16
ENSMUSG00000030465 Psd3 pleckstrin and Sec7 domain containing 3
ENSMUSG00000038764 Ptpn3 protein tyrosine phosphatase, non-receptor type 3
ENSMUSG00000053141 Ptprt protein tyrosine phosphatase, receptor type, T
ENSMUSG00000068748 Ptprz1 protein tyrosine phosphatase, receptor type Z, polypep-
tide 1
ENSMUSG00000037098 Rab11fip3 RAB11 family interacting protein 3 (class II)
Continued on next page
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Table S2 – Continued from previous page
Ensembl ID symbol name
ENSMUSG00000027652 Ralgapb Ral GTPase activating protein, beta subunit (non-
catalytic)
ENSMUSG00000075376 Rc3h2 ring finger and CCCH-type zinc finger domains 2
ENSMUSG00000042453 Reln reelin
ENSMUSG00000050310 Rictor RPTOR independent companion of MTOR, complex 2
ENSMUSG00000020448 Rnf185 ring finger protein 185
ENSMUSG00000038685 Rtel1 regulator of telomere elongation helicase 1
ENSMUSG00000021313 Ryr2 ryanodine receptor 2, cardiac
ENSMUSG00000075318 Scn2a1 sodium channel, voltage-gated, type II, alpha 1
ENSMUSG00000028064 Sema4a sema domain, immunoglobulin domain (Ig), transmem-
brane domain (TM) and short cytoplasmic domain,
(semaphorin) 4A
ENSMUSG00000005089 Slc1a2 solute carrier family 1 (glial high affinity glutamate
transporter), member 2
ENSMUSG00000023032 Slc4a8 solute carrier family 4 (anion exchanger), member 8
ENSMUSG00000019769 Syne1 synaptic nuclear envelope 1
ENSMUSG00000062542 Syt9 synaptotagmin IX
ENSMUSG00000053580 Tanc2 tetratricopeptide repeat, ankyrin repeat and coiled-coil
containing 2
ENSMUSG00000023923 Tbc1d5 TBC1 domain family, member 5
ENSMUSG00000039230 Tbcd tubulin-specific chaperone d
ENSMUSG00000032186 Tmod2 tropomodulin 2
ENSMUSG00000009470 Tnpo1 transportin 1
ENSMUSG00000019820 Utrn utrophin
ENSMUSG00000046230 Vps13a vacuolar protein sorting 13A (yeast)
ENSMUSG00000045962 Wnk1 WNK lysine deficient protein kinase 1
ENSMUSG00000047694 Yipf6 Yip1 domain family, member 6
ENSMUSG00000020812 RIKEN cDNA 1810032O08
ENSMUSG00000053081 RIKEN cDNA 1700069B07
ENSMUSG00000072847 RIKEN cDNA A530017D24
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Table S3: 23 genes with differential isoform usage (DU only p-value < 0.01) between the two
alleles of the haloperidol treated F1(129×PWK) mouse, but no differential isoform usage
(DU only p-value > 0.1) comparing the two alleles of the placebo treated F1(129×PWK)
mouse.
Ensembl ID symbol name
ENSMUSG00000006638 Abhd1 abhydrolase domain containing 1
ENSMUSG00000005686 Ampd3 adenosine monophosphate deaminase 3
ENSMUSG00000004446 Bid BH3 interacting domain death agonist
ENSMUSG00000022617 Chkb choline kinase beta
ENSMUSG00000026816 Gtf3c5 general transcription factor IIIC, polypeptide 5
ENSMUSG00000031787 Katnb1 katanin p80 (WD40-containing) subunit B 1
ENSMUSG00000058740 Kcnt1 potassium channel, subfamily T, member 1
ENSMUSG00000039682 Lap3 leucine aminopeptidase 3
ENSMUSG00000026792 Lrsam1 RIKEN cDNA 4930555K19
ENSMUSG00000024085 Man2a1 mannosidase 2, alpha 1
ENSMUSG00000029822 Osbpl3 oxysterol binding protein-like 3
ENSMUSG00000021846 Peli2 pellino 2
ENSMUSG00000033628 Pik3c3 phosphoinositide-3-kinase, class 3
ENSMUSG00000005225 Plekha8 pleckstrin homology domain containing, family A
(phosphoinositide binding specific) member 8
ENSMUSG00000026035 Ppil3 peptidylprolyl isomerase (cyclophilin)-like 3
ENSMUSG00000036202 Rif1 Rap1 interacting factor 1 homolog (yeast)
ENSMUSG00000001054 Rmnd5b required for meiotic nuclear division 5 homolog B
(S. cerevisiae)
ENSMUSG00000052656 Rnf103 ring finger protein 103
ENSMUSG00000027273 Snap25 synaptosomal-associated protein 25
ENSMUSG00000043079 Synpo synaptopodin
ENSMUSG00000040389 Wdr47 WD repeat domain 47
ENSMUSG00000001017 RIKEN cDNA 2500003M10
ENSMUSG00000044600 RIKEN cDNA 9130011J15
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